It is important to empower new entrants into the business. With businesses looking to build up talent pipelines and a rise in employer demand predicted, entrusting new talent with responsibility ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time between ...

Men with advanced prostate cancer are being denied access to a breakthrough treatment for the disease – despite it being low cost, and based on UK research. The chemotherapy drug docetaxel has ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

“AI has arrived,” British Prime Minister Keir Starmer declared in a recent speech. “Our defining opportunity is here - and together, we will harness it”, he added, praising the potential ...

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested outside ...

As debate about the usefulness and ethics of generative artificial intelligence (AI) continues, the pharmaceutical industry needs to consider the advantages it can offer, especially for ...

Cancer is the second leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, according to the World Health Organization. In 2020, the US National Cancer institute had a ...

Going beyond the pill is proving to be a win/win for patients and pharma alike – because improved outcomes are better for everyone. With growing numbers of people around the world living with ...

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting the ...